Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"NAFLD/NASH"”.
-
CODING E NON-CODING RNA COME BIOMARCATORI DI SEVERITA’ DI NAFLD E DI FIBROSI
… non alcolica (Non-Alcoholic Fatty Liver Disease, NAFLD) è l’epatopatia cronica più comune nei paesi industrializzati con una prevalenza del 20-30% nella popolazione generale. La NAFLD comprende un vasto spettro di patologie epatiche e sebbene sia generalmente considerata una condizione benigna, …
-
Mechanistic Elucidation of the Function of Sirtuin 6 in the Regulation of Liver Fibrosis
Hepatic fibrosis is a cellular repair mechanism that is initiated upon prolonged damage to the liver, resulting in an accumulation of excess extracellular matrix. This eventually leads to the formation of scar tissue, which disrupts the hepatic architecture and causes liver dysfunction. Hepatic …
-
A systems biology approach to the pathogenesis and progression of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases ranging from simple steatosis (isolated hepatic fat accumulation) to steatohepatitis (NASH; hepatic fat accumulation with lipotoxicity, hepatic cell damage and inflammation), eventually progressing to fibrosis, cirrhosis and …
-
NONCANONICAL PYROPTOSIS PROMOTES NONALCOHOLIC STEATOHEPATITIS VIA LIPID PEROXIDATION AND TRAINED IMMUNITY
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of abnormal liver function in countries with western-style high fat, high cholesterol diets. Liver damage associated with NAFLD may lead to liver cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). …
-
Mitochondrial Uncouplers: Development as Therapeutics for Metabolic Diseases
… relevance is non-alcoholic fatty liver disease (NAFLD) and its advanced disease state known as non-alcoholic steatohepatitis (NASH), as it has had a documented rise in prevalence parallel to that observed with obesity. Currently there are no FDA approved therapeutics for NAFLD or NASH, with the …